

*TPW*



Attorney Docket No.: 6567.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Sorensen et al.

Serial No.: 10/735,963

Group Art Unit: 1614

Filed: December 15, 2003

Examiner: To be assigned

For: Substituted Homopiperidine, Piperidine or Pyrrolidine Derivatives

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

MS : IDS  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


on February 2, 2005

Rashida Haji

(name of person mailing paper)

*Rashida Haji*

(signature of person mailing paper)



Attorney Docket No.: 6567.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Sorensen et al.

Application No.: 10/735,963

Group Art Unit: 1614

Filed: December 15, 2003

Examiner: To be assigned

For: Substituted Homopiperidine, Piperidine or Pyrrolidine Derivatives

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. US Patent No. 5633382
2. US 2003/0191112
3. US Patent No. 6673829
4. WO 03/103669
5. WO 93/20061


6. Apelt et al., J. Med. Chem., (2002), Vol. 45, pages 1128-1141
7. Apodaka et al., J. Med. Chem., (2003), Vol. 46, pages 3938-3944
8. Kitbunnadaj et al., J. Med. Chem., (2003), Vol. 46, pages 5445-5457
9. International Search Report dated 06/07/2004.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The supplemental information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Inc. Deposit Account No. 14-1447.

Respectfully submitted,

Date: February 2, 2005

  
Rosemarie R. Wilk-Orescan, Reg. No. 45,220  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

**Use the following customer number for all correspondence regarding this application.**

**23650**

PATENT TRADEMARK OFFICE